HTGC

Business Context and Reporting Period

Company: Hercules Technology Growth Capital, Inc. (Hercules)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Hercules is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC). It provides debt and equity growth capital to technology-related and life-science companies. The company completed its Initial Public Offering (IPO) on June 11, 2005, raising approximately $71 million net of costs.

Key Financial Metrics

Material Changes vs. Prior Period

• Portfolio Growth: Total investment portfolio value increased from $16.7 million at December 31, 2004, to $130.4 million at September 30, 2005, driven by the deployment of IPO proceeds and bridge financing.
• Profitability: The company transitioned from a net loss of $335,823 for the three months ended September 30, 2004, to a net increase in net assets of $1,561,924 for the same period in 2005. This shift is attributed to significant investment income generation ($3.4M interest vs. $49k in 2004) offset by higher operating expenses due to public company status and increased headcount.
• Capital Structure: Shares outstanding increased from 2.06 million (Dec 31, 2004) to 9.80 million (Sep 30, 2005) following the IPO and warrant exercises. The company incurred $25 million in short-term debt via a bridge loan facility in April 2005.
• Unrealized Gains: Recognized net unrealized appreciation of $1.72 million for the nine months ended September 30, 2005, compared to zero in the prior year period.

Outlook, Risks, and Management Commentary

• Liquidity and Capital Resources: The company has approximately $60 million of borrowing capacity available under a $100 million securitized credit facility with Citigroup (undrawn as of Sept 30, 2005, though $5 million was drawn in October 2005). Management anticipates funding future investments through a combination of debt and equity capital.
• Dividends: On October 27, 2005, the company declared its first quarterly dividend of $0.025 per share. The company intends to elect Regulated Investment Company (RIC) status by January 1, 2006, to avoid corporate-level taxes on distributed income.
• Investment Strategy: The portfolio is concentrated in technology and life sciences, with 91.1% of investments rated Grade 2. The weighted average yield to maturity is 12.97%.
• Risks:
  • Valuation Uncertainty: Investments are in private companies with no readily available market value; fair value is determined in good faith by the Board, creating potential for material differences between recorded and realized values.
  • Leverage Risk: The company utilizes debt (currently $25M bridge loan) to enhance returns, which magnifies the impact of asset value fluctuations on net asset value.
  • Regulatory Compliance: Failure to maintain BDC or RIC status could result in adverse tax consequences and reduced operating flexibility.
  • Concentration Risk: Significant exposure to the technology and life-science sectors, which are subject to volatility and rapid obsolescence.

Key Facts for Investor Verification

• Bridge Loan Terms: Verify the interest rate reset on the $25 million Alcmene bridge loan, which was amended to LIBOR + 5.6% (approx. 9.76% at period end) through Dec 31, 2005, and 13.5% thereafter.
• Citigroup Facility Utilization: Confirm the status of the $100 million securitized facility, noting the 55% advance rate and the $5 million drawdown that occurred in October 2005 (subsequent to the reporting period).
• Portfolio Valuation: Review the specific valuation methodologies used for the $130.4 million portfolio, particularly for the 7.3% of assets rated Grade 4 (higher risk).
• RIC Election Timeline: Monitor the company's progress in meeting the 90% distribution requirement and asset diversification tests necessary to qualify as a RIC by January 1, 2006.
• Unfunded Commitments: Note the $23.2 million in unfunded commitments to portfolio companies, representing potential future cash outflows.